Garuda Therapeutics is pioneering the development of off-the-shelf hematopoietic stem cell (HSC) therapies aimed at treating a wide array of severe and life-threatening diseases. Their innovative platform technology focuses on generating self-renewing blood stem cells that are designed to provide patients with rapid access to consistent, durable, and HLA-compatible therapies without the need for donor or patient cells. This groundbreaking approach has the potential to address over 70 diseases, significantly enhancing treatment accessibility and efficiency by eliminating the dependency on traditional stem cell transplants, which often require matching donors.

The company’s leadership comprises experts in blood stem cell research and bone marrow transplants, ensuring a robust foundation for advancing their therapeutic offerings. Garuda's commitment to innovation is further underscored by its recent recognition as the "Overall Cell Biology Company of the Year" by BioTech Breakthrough, highlighting its significant contributions to the life sciences and biotechnology sectors. With substantial funding and strategic partnerships, Garuda Therapeutics is well-positioned to lead the way in transforming blood stem cell therapies and improving patient outcomes.

United States

Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com

Garuda Therapeutics

Company Details